NCT04424719Recruiting
Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)
Source: ClinicalTrials.gov · Last updated 3 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 700 (estimated)
- First submitted
- 18 May 2020
- Start date
- 8 Jul 2020
- Primary completion date
- 7 Jul 2037
- Lead sponsor
- Institut Curie
- Diseases
- Melanoma
- NCT number
- NCT04424719
What you commit to
- Study type: Interventional
- Planned participants: 700
- From 8 Jul 2020 to the primary completion date, 7 Jul 2037
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any social, medical or psychological condition making the research process impossible.
Other
- Patient without french social insurance.
Who the study is looking for
- Patient aged of 18 years or more.
- Patient with uveal melanoma with high metastatic relapse risk defined as :
- T2b/c/d ou ≥ T3,
- or chromosom 3 or chromosom 8 abnormality by CGH array.
- Completion of treatment of the primary tumor ≤ 2 months.
- Patient able to comply with the schedule of visits and blood samples of the study.
- Signed informed consent form or legal representative.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Curie Coordinator of this site? Confirm its status | Paris | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.